Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
J. M. Lafky
No relevant relationships to disclose
B. M. Bot
No relevant relationships to disclose
B. W. Morlan
No relevant relationships to disclose
S. K. Anderson
No relevant relationships to disclose
T. K. Kimlinger
No relevant relationships to disclose
T. M. Halling
No relevant relationships to disclose
S. Kumar
Consultant or Advisory Role - Merck (U)
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
J. T. Reynolds
No relevant relationships to disclose
P. J. Stella
No relevant relationships to disclose
S. R. Dakhil
No relevant relationships to disclose
W. S. Loui
No relevant relationships to disclose
S. R. Alberts
Consultant or Advisory Role - Bayer (U); Bristol-Myers Squibb (U)
Research Funding - Bayer; Bristol-Myers Squibb
A. Grothey
Consultant or Advisory Role - Bayer (U); Roche/Genentech (U)
Research Funding - Bayer; Roche/Genentech